Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles.
Dispersions of insulin poly(isobutylcyanoacrylate) nanoparticles were obtained by anionic in situ polymerization using aqueous pluronic acid solution. Results showed a decrease in particle size diameter by increasing the pluronic acid concentration. Nanoparticles prepared in the presence of 2.5% pluronic acid resulted in particles of 85 nm average diameter and 59% intra-particular insulin load without the use of the oily core [Damge, C., Michel, M., Aprahamian, M., Couveur, P., 1988. New approach for oral administration with polycyanoacrylate nanocapsules as drug carrier. Diabetes 37, 246-251]. In vivo testing was performed on streptozocin induced diabetic rats. The subcutaneous injection of insulin nanoparticles was able to prolong its duration of hypoglycemic effect from 6 to 72 h. Effective oral absorption of the entrapped insulin was significantly better (p<0.01) when compared with non-encapsulated insulin or the control experiments.
Mesiha
Mounir S
MS
Division of Pharmaceutical Sciences, Arnold and Marie Schwartz College of Pharmacy, Long Island University, 75 DeKalb Avenue, Brooklyn, NY 11201, USA. mmesiha@liu.edu
Sidhom
Madiha B
MB
Fasipe
Babatunde
B
D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003487:Cyanoacrylates / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004659:Enbucrilate; D006801:Humans; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008297:Male; D049329:Nanostructures; D011108:Polymers / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D040521:Subcutaneous Tissue / Q000187:drug effects / Q000378:metabolism
D001786:Blood Glucose; D003487:Cyanoacrylates; D007328:Insulin; D011108:Polymers; D004659:Enbucrilate